Anti-Tumor Necrosis Factor Receptor 2 Antibody Combined With Anti-PD-L1 Therapy Exerts Robust Antitumor Effects in Breast Cancer
Breast cancer is a leading type of malignant tumor in women; however, the immunotherapy in breast cancer is still underappreciated. In this study, we demonstrated that tumor necrosis factor receptor 2 (TNFR2) is highly expressed in both breast tumor tissue and tumor-infiltrating immunosuppressive CD...
Enregistré dans:
Auteurs principaux: | Qiang Fu, Qian Shen, Jin Tong, Liu Huang, Yi Cheng, Wei Zhong |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Frontiers Media S.A.
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/e1efb576d3b34b5292cfa5d81a039b9a |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Anti-TNFR1 targeting in humanized mice ameliorates disease in a model of multiple sclerosis
par: Sarah K. Williams, et autres
Publié: (2018) -
Cyclophosphamide abrogates the expansion of CD4+Foxp3+ regulatory T cells and enhances the efficacy of bleomycin in the treatment of mouse B16-F10 melanomas
par: Ping Li, et autres
Publié: (2021) -
Progranulin as a Potential Therapeutic Target in Immune-Mediated Diseases
par: Lan YJ, et autres
Publié: (2021) -
Effects of early administration of insulin-like growth factor-1 on cognitive function in septic encephalopathy
par: Yang Y, et autres
Publié: (2019) -
Plasminogen Activating Inhibitor-1 Might Predict the Efficacy of Anti-PD1 Antibody in Advanced Melanoma Patients
par: Kentaro Ohuchi, et autres
Publié: (2021)